Ocugen Inc
Change company Symbol lookup
Select an option...
OCGN Ocugen Inc
DIA SPDR® Dow Jones Industrial Average ETF Trust
SPY SPDR® S&P 500 ETF Trust
ABBNY Abb Ltd
FCF First Commonwealth Financial Corp
ARMN Aris Mining Corp
IBM International Business Machines Corp
JPM JPMorgan Chase & Co
GEHC GE Healthcare Technologies Inc
GE General Electric Co
Go

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Biotechnology | Small Cap Value

Ocugen, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing gene and cell therapies, biologics, and vaccines that improve health for patients across the globe. The Company's technology pipeline includes modifier gene therapy platform, regenerative medicine cell therapy platform, and biologic therapies for retinal diseases. It is developing COVAXIN, which is a whole-virion inactivated intramuscular COVID-19 vaccine candidate for the North American market. It is also developing a inhaled mucosal vaccine platform, which includes OCU500, a bivalent COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and bivalent COVID-19 vaccine. Its modifier gene therapy platform is focused on addressing various retinal diseases, including retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), and Stargardt disease, with a single mutation-agnostic therapy.

Price: Delayed
$0.3997

Day's Change: -0.0007 (-0.17%)

Bid: --

Ask: --

B/A Size: --

Day's High: 0.408

Day's Low: 0.3991

Volume (Above Average) Today's volume of 727,584 shares is on pace to be greater than OCGN's 10-day average volume of 1,271,996 shares.: 727,584

There is no peer information for OCGN.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for varies.

Market data and information provided by Morningstar.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.